eligard 7.5 mg powder and solvent for solution for injection
astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 7.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
leuprorelin sandoz
sandoz new zealand limited - leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin - subcutaneous implant - 3.6 mg - active: leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin excipient: polyglactin - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma
leuprorelin sandoz
sandoz new zealand limited - leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg - subcutaneous implant - 5 mg - active: leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg excipient: poly(lactide) - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma
zoladex implants 3.6mg
aa-pharma ul. sapiezynska 10, 00-215 warsawa, poland - goserelin acetate - implant - goserelin acetate 3.6 gram(s) - endocrine therapy
zoladex la implants 10.8mg
aa-pharma ul. sapiezynska 10, 00-215 warsawa, poland - goserelin acetate - implant - goserelin acetate 10.8 gram(s) - endocrine therapy
eligard 22.5 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
eligard 45 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
eligard 7.5 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard 7.5 mg is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer combination with radiotherapy.
zoladex depot 3.6 mg implante s.c.
astrazeneca uk ltd. - goserelin (acetato) - goserelin (acetato)....3.6 mg.
zoladex la 10.8 mg implante s.c.
astrazeneca uk ltd. - goserelin (acetato) - goserelin (acetato)....10.8 mg.